These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 25708606)

  • 21. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
    Osman NI; Chapple CR; Tammela TL; Eisenhardt A; Oelke M
    World J Urol; 2015 May; 33(5):697-706. PubMed ID: 25712312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Matsumoto S; Kasamo S; Hashizume K
    Low Urin Tract Symptoms; 2020 Jan; 12(1):86-91. PubMed ID: 31464384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia].
    Krivoborodov GG; Tur EI
    Urologiia; 2019 Jun; (2):67-72. PubMed ID: 31162905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
    Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study.
    Masciovecchio S; Di Pasquale AB; Ranieri G; Romano G; Di Clemente L
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4941-4945. PubMed ID: 29164564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
    Lepor H; Hill LA
    Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies.
    Eisenhardt A; Schneider T; Cruz F; Oelke M
    World J Urol; 2014 Oct; 32(5):1119-25. PubMed ID: 24442560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.
    Ding H; Du W; Hou ZZ; Wang HZ; Wang ZP
    Asian J Androl; 2013 Jan; 15(1):121-8. PubMed ID: 23223034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Profile of silodosin].
    Montorsi F
    Urologiia; 2013; (2):112-4, 116-7. PubMed ID: 23789376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting the Pharmacodynamic Uroselectivity of
    Quaresma BMCS; Pimenta AR; Santos da Silva AC; Pupo AS; Romeiro LAS; Silva CLM; Noël F
    J Pharmacol Exp Ther; 2019 Oct; 371(1):106-112. PubMed ID: 31285236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A place of silodosin in the treatment of LUTS/BPH according to evidence-based medicine and real clinical practice].
    Kotov SV; Bogdanov DA
    Urologiia; 2021 Nov; (5):94-98. PubMed ID: 34743440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.